Author: Matsumura, Yasuhiro

Source: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Cu, Volume 8, Number 4, December 2009 , pp. 377-386(10)

Publisher: Bentham Science Publishers

Abstract:

Glucocorticoids (GCs) represent the cornerstone of treatment of patients with bronchial asthma; however, inflammation in bronchial asthma is sometimes incompletely controlled. GCs switch on the expression of anti-inflammatory genes by binding to DNA and recruiting transcriptional coactivator molecules. In contrast, they can switch off activated inflammatory genes by recruiting transcriptional repressor molecules such as histone deacetylase (HDAC) 2.

Proinflammatory transcriptional element activator protein-1 (AP-1) and transcription factor nuclear factor kappa B (NF- κB), and upstream kinase p38 and c-Jun-N-terminal kinase (JNK) amplify inflammation and resistance to the actions of GCs. The activity of histoneacetyltransferase (HAT) and HDAC influences the expression of inflammatory genes. Cytokines, inflammatory mediators, allergens, viral or bacterial infections, oxidative stress, smoking, and vitamin D deficiency may all lead to a worsened clinical outcome by influencing these pathways.

Conventional therapy acts by inhibiting NF-κB, enhancing glucocorticoid receptor (GR) functions, and restoring HDAC activity, resulting in helpful add-on therapy. Targeting kinases such as inhibitor of κB kinase (IKK)2, mitogen activated protein (MAP) kinase (MAPK)s and phospho-inositol (PI)3 kinase (PI-3K) should be effective as therapy. Decoy oligonucleotides for AP-1and NF-κB are also candidates for the treatment of glucocorticoid-resistant (GC-R) asthma.

Since various factors affect GC response, the pathogenesis of GC-R asthma is considered to be heterogeneous. Most GC nonresponsiveness in these patients is relative and not absolute, suggesting that resistance is dependent on the intensity of localized inflammation. A better understanding of the inflammatory mechanisms of asthma may signal the management of GC-R asthma.

Keywords: Glucocorticoid (GC); glucocorticoid-resistant (GC-R) asthma; glucocorticoid receptor (GR); MAP kinase (MAPK); c-Jun-N-terminal kinase (JNK); activator protein-1 (AP-1); nuclear factor kappa B (NF-κB); histone deacetylase (HDAC)

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187152309789839055

Publication date: 2009-12-01

More about this publication?

• Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Anti-Inflammatory & Anti-Allergy Agents.
  
  Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Anti-Inflammatory & Anti-Allergy Medicinal Chemistry.
  
  Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Anti-Inflammatory & Anti-Allergy Agents drug discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Matsumura, Yasuhiro

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers